Equity
€44,788 ▲ 2.3%
Pharmed has made a profit in every financial year since 2014.
Pharmed
Lifetime
12 annual accounts with figures on one time axispeak €139,484 (2022)
€71,199▼ 45.3%
peak €47,711 (2024)
€1,022▼ 97.9%
peak €44,788 (2025)
€44,788▲ 2.3%
€139,013▼ 9.9%
peak 1.4 FTE (2020)
-not published
Board1 name since 2021
1 director
Documentsfilings and deeds
27-08-202627 days late
2025micro format
Gross margin from €130,261 to €71,199Result from €47,711 to €1,022Investments €18,920Cash from €33,369 to €14,394
Key points
from the 2025 annual accountsTurnover
≈ €340,000 estimated
The micro format states no turnover.
Debts
€139,013 76% of the balance sheet
Suppliers 73%Taxes and wages 24%Other 3%
Investments
€18,920 2.1 × depreciation
Green is investment, beige is depreciation. Machinery stands 52.2% higher than in 2024.
Staff
1 employees on 31-12-2025
In 2025, 1 person joined and 1 left.
Filings
12 annual accounts since 2014
Nine of the last ten came late. The 2019 accounts came latest: 32 days after the end of the period.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 4,508 companies had the same profile as Pharmed has now. Each dot stands for 12 companies, two years later.
96.8%
were still trading
1.6%
stopped another way
1.4%
went bankrupt
Another 0.2% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,448 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 4,508 companies, not a prediction for Pharmed. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0543397364
Change of role: , from manager to director
Director discharge: (manager) · Gazette deed
First establishment
Josaphatstraat 73, Schaerbeek
Incorporation
published on 02-01-2014 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| Pharmed Schaerbeek | €183,800 | €71,199 | 24.4% | - |
| LE LUMEÇON Brussels | €213,394 | €57,375 | 51.8% | 0 |
| PHARMACIE DU PETIT RY Ciney | €186,402 | €62,395 | 96.9% | - |
| PHARMACIE SWINNEN Liège | €214,057 | €64,010 | 65.1% | 0.7 |
| Ilse Verstraeten Sint-Truiden | €178,548 | €74,847 | 97.9% | - |
| GILSON MARIE-CLAIRE Vaux-sur-Sûre | €221,736 | €68,923 | 87.0% | - |
| LYNAPHARMA Sint-Gillis (bij-Brussel) | €177,178 | €60,362 | 82.7% | - |
These companies have the same main activity as Pharmed: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €177,000 and €222,000, founded between 2011 and 2016.
Official details
Source: KBO- Status
- Active since 18-12-2013Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Joint committee
- 313Pharmacies and pricing offices · annual accounts 2025
- Establishment unit
- 2.225.647.4791030 Schaerbeek, since 02-01-2014
- Financial year end
- 31 December
- Peppol
- Reachable since 12-12-2025
Insights on Pharmed
Pharmed files the micro format. That format states no turnover. The gross margin rose from €45,877 in 2014 to €71,199 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about Pharmed
- What is the company number of Pharmed?
- The company number of Pharmed is 0543.397.364. The VAT number is the same number with BE in front: BE 0543.397.364.
- Where is Pharmed based?
- The registered office is at Josaphatstraat 73, 1030 Schaerbeek.Company details
- What does Pharmed do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of Pharmed?
- Pharmed is a private limited company (BV).
- When was Pharmed founded?
- Pharmed was founded on 18-12-2013.
- Is Pharmed still active?
- Yes, Pharmed is an active enterprise in the KBO register.
- How many employees does Pharmed have?
- Pharmed had an average of 1 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does Pharmed fall under?
- In its 2025 annual accounts, Pharmed states joint committee 313 (Pharmacies and pricing offices).
- What is the turnover of Pharmed?
- The turnover in financial year 2025 is ≈ €340,000. This figure is estimated from the gross margin of €71,199 and 45 comparable companies (NACE 477). It probably lies between €180,000 and €470,000.
- Is Pharmed profitable?
- In financial year 2025, Pharmed made a profit of €1,022.
- Where can I find the annual accounts of Pharmed?
- Pharmed filed 12 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of Pharmed due?
- Pharmed must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.